NcodiN | $18,456,480 | (Nov 21, 2025)
Voio | $8,600,000 | (Nov 21, 2025)
Stuut | $29,500,000 | (Nov 21, 2025)
BAKX Therapeutics
United States
- New York | Boston
- 18/11/2021
- Series A
- $25,000,000
We create targeted cancer therapies through unique insights into the conformationally dynamic protein drivers of the mitochondrial apoptosis pathway combined with structure-based drug design and computational simulations
We have built an integrated & iterative platform based on knowledge, experimentation, and simulation that allows us to better interrogate and harness the power of regulated apoptosis
We are developing a suite of orally active therapeutics which can act as single agents or in combination with other oncology therapies to create better and lasting outcomes for cancer patients
- Industry Biotechnology
- Website https://bakxtx.com/
- LinkedIn https://www.linkedin.com/company/bakxtx/
Related People
Sree KantFounder
United States -
New York, New York
Life Sciences thought leader and executive. Former head of Corporate Development at Life Biosciences; Former head of partnering strategy for Pfizer. Former healthcare principal at Boston Consulting.
Made Card | $8,000,000 | (Nov 21, 2025)
Poly(US) | $8,000,000 | (Nov 21, 2025)
Runlayer | $11,000,000 | (Nov 21, 2025)
AI Proteins | $41,500,000 | (Nov 21, 2025)
Automat | $15,500,000 | (Nov 21, 2025)
EQORE | $1,700,000 | (Nov 21, 2025)
Poppy Flowers | $2,700,000 | (Nov 21, 2025)
WellBeam Inc | $10,000,000 | (Nov 21, 2025)
Revenium | $13,500,000 | (Nov 21, 2025)